▎WuXiEdited by Kant Content Team

Recently, the prestigious medical journal *The New England Journal of Medicine* published the phase 3 clinical trial results of Bristol-Myers Squibb Company’s重磅PD-1 inhibitor Opdivo (nivolumab) in combination with chemotherapy for the first-line treatment of patients with advanced classical Hodgkin lymphoma. The data shows,At a median follow-up time of 2.1 years, the 2-year progression-free survival rate for patients treated with the Opdivo combination therapy reached 92%, and the 2-year overall survival rate reached 99%. These data support the FDA's approval of Opdivo combination therapy as a first-line treatment for such patients.

This randomized Phase 3 clinical trial included 970 newly diagnosed advanced classical Hodgkin lymphoma patients in the efficacy analysis, with patients randomly receiving treatment with either Opdivo combined with chemotherapy (N+AVD) or the CD30-targeted antibody-drug conjugate (ADC) Adcetris combined with chemotherapy (BV+AVD).

At a median follow-up time of 2.1 years,Opdivo Combination Therapy Reduces Risk of Disease Progression or Death by 55% Compared to Active Control (HR=0.45, 95% CI, 0.30-0.65). The 2-Year Progression-Free Survival Rate was 92% in the Opdivo Group vs 83% in the Active Control Group.

▲Opdivo Combination Therapy Improves Progression-Free Survival Rate (Image Source: Reference [2])

In terms of overall survival rate, the 2-year overall survival rate in the Opdivo group reached 99%, with 7 patients deceased, while the 2-year overall survival rate in the active comparator group was 98%, with 14 patients deceased.Opdivo combination therapy reduced the risk of death by 61% (HR=0.39, 95% CI, 0.15-1.03).

Opdivo is a PD-1 immune checkpoint inhibitor designed to help restore anti-tumor immune responses in the human body. Opdivo has become an important treatment option across various types of cancer, and to date, the Opdivo clinical development program has treated over 35,000 patients.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.